Bone mass density following developmental exposures to perfluoroalkyl substances (PFAS): a longitudinal cohort study [Inkl. Correction]

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Bone mass density following developmental exposures to perfluoroalkyl substances (PFAS) : a longitudinal cohort study [Inkl. Correction]. / Blomberg, Annelise; Mortensen, Jann; Weihe, Pál; Grandjean, Philippe.

I: Environmental Health, Bind 21, 113, 2022.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Blomberg, A, Mortensen, J, Weihe, P & Grandjean, P 2022, 'Bone mass density following developmental exposures to perfluoroalkyl substances (PFAS): a longitudinal cohort study [Inkl. Correction]', Environmental Health, bind 21, 113. https://doi.org/10.1186/s12940-022-00929-w

APA

Blomberg, A., Mortensen, J., Weihe, P., & Grandjean, P. (2022). Bone mass density following developmental exposures to perfluoroalkyl substances (PFAS): a longitudinal cohort study [Inkl. Correction]. Environmental Health, 21, [113]. https://doi.org/10.1186/s12940-022-00929-w

Vancouver

Blomberg A, Mortensen J, Weihe P, Grandjean P. Bone mass density following developmental exposures to perfluoroalkyl substances (PFAS): a longitudinal cohort study [Inkl. Correction]. Environmental Health. 2022;21. 113. https://doi.org/10.1186/s12940-022-00929-w

Author

Blomberg, Annelise ; Mortensen, Jann ; Weihe, Pál ; Grandjean, Philippe. / Bone mass density following developmental exposures to perfluoroalkyl substances (PFAS) : a longitudinal cohort study [Inkl. Correction]. I: Environmental Health. 2022 ; Bind 21.

Bibtex

@article{5d4467ed21b54882bd9b002f0cb17f13,
title = "Bone mass density following developmental exposures to perfluoroalkyl substances (PFAS): a longitudinal cohort study [Inkl. Correction]",
abstract = "Background: Environmental exposures to industrial chemicals, including perfluoroalkyl substances (PFAS), may play a role in bone development and future risk of osteoporosis. However, as prospective evidence is limited, the role of developmental PFAS exposures in bone density changes in childhood is unclear. The objective of this study was to estimate associations between serum-PFAS concentrations measured in infancy and early childhood and areal bone mineral density (aBMD) measured at age 9 years in a birth cohort of children from the Faroe Islands. Methods: We prospectively measured concentrations of five PFAS in cord serum and serum collected at 18 months, 5 years and 9 years, and conducted whole-body DXA scans at the 9-year clinical visit. Our study included 366 mother-child pairs with DXA scans and at least one PFAS measurement. We estimated covariate-adjusted associations of individual PFAS concentrations with age-, sex- and height-adjusted aBMD z-scores using multivariable regression models and applied formal mediation analysis to estimate the possible impact of by several measures of body composition. We also evaluated whether associations were modified by child sex. Results: We found PFAS exposures in childhood to be negatively associated with aBMD z-scores, with the strongest association seen for perfluorononanoic acid (PFNA) at age 5 years. A doubling in age-5 PFNA was associated with a 0.15 decrease in aBMD z-score (95% CI: − 0.26, − 0.039). The PFNA-aBMD association was significantly stronger in males than females, although effect modification by sex was not significant for other PFAS exposures. Results from the mediation analysis suggested that any potential associations between aBMD and 18-month PFAS concentrations may be mediated by total body fat and BMI, although most estimated total effects for PFAS exposures at age 18 months were non-significant. PFAS exposures at age 9 were not associated with age-9 aBMD z-scores. Conclusions: The PFAS-aBMD associations identified in this and previous studies suggest that bone may be a target tissue for PFAS. Pediatric bone density has been demonstrated to strongly track through young adulthood and possibly beyond; therefore, these prospective results may have important public health implications.",
keywords = "Bone mass density, Childhood, DXA, Per- and polyfluoroalkyl substances, PFAS",
author = "Annelise Blomberg and Jann Mortensen and P{\'a}l Weihe and Philippe Grandjean",
note = "Correction: 10.1186/s12940-023-00968-x Link: https://ehjournal.biomedcentral.com/articles/10.1186/s12940-023-00968-x Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
doi = "10.1186/s12940-022-00929-w",
language = "English",
volume = "21",
journal = "Environmental Health",
issn = "1476-069X",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Bone mass density following developmental exposures to perfluoroalkyl substances (PFAS)

T2 - a longitudinal cohort study [Inkl. Correction]

AU - Blomberg, Annelise

AU - Mortensen, Jann

AU - Weihe, Pál

AU - Grandjean, Philippe

N1 - Correction: 10.1186/s12940-023-00968-x Link: https://ehjournal.biomedcentral.com/articles/10.1186/s12940-023-00968-x Publisher Copyright: © 2022, The Author(s).

PY - 2022

Y1 - 2022

N2 - Background: Environmental exposures to industrial chemicals, including perfluoroalkyl substances (PFAS), may play a role in bone development and future risk of osteoporosis. However, as prospective evidence is limited, the role of developmental PFAS exposures in bone density changes in childhood is unclear. The objective of this study was to estimate associations between serum-PFAS concentrations measured in infancy and early childhood and areal bone mineral density (aBMD) measured at age 9 years in a birth cohort of children from the Faroe Islands. Methods: We prospectively measured concentrations of five PFAS in cord serum and serum collected at 18 months, 5 years and 9 years, and conducted whole-body DXA scans at the 9-year clinical visit. Our study included 366 mother-child pairs with DXA scans and at least one PFAS measurement. We estimated covariate-adjusted associations of individual PFAS concentrations with age-, sex- and height-adjusted aBMD z-scores using multivariable regression models and applied formal mediation analysis to estimate the possible impact of by several measures of body composition. We also evaluated whether associations were modified by child sex. Results: We found PFAS exposures in childhood to be negatively associated with aBMD z-scores, with the strongest association seen for perfluorononanoic acid (PFNA) at age 5 years. A doubling in age-5 PFNA was associated with a 0.15 decrease in aBMD z-score (95% CI: − 0.26, − 0.039). The PFNA-aBMD association was significantly stronger in males than females, although effect modification by sex was not significant for other PFAS exposures. Results from the mediation analysis suggested that any potential associations between aBMD and 18-month PFAS concentrations may be mediated by total body fat and BMI, although most estimated total effects for PFAS exposures at age 18 months were non-significant. PFAS exposures at age 9 were not associated with age-9 aBMD z-scores. Conclusions: The PFAS-aBMD associations identified in this and previous studies suggest that bone may be a target tissue for PFAS. Pediatric bone density has been demonstrated to strongly track through young adulthood and possibly beyond; therefore, these prospective results may have important public health implications.

AB - Background: Environmental exposures to industrial chemicals, including perfluoroalkyl substances (PFAS), may play a role in bone development and future risk of osteoporosis. However, as prospective evidence is limited, the role of developmental PFAS exposures in bone density changes in childhood is unclear. The objective of this study was to estimate associations between serum-PFAS concentrations measured in infancy and early childhood and areal bone mineral density (aBMD) measured at age 9 years in a birth cohort of children from the Faroe Islands. Methods: We prospectively measured concentrations of five PFAS in cord serum and serum collected at 18 months, 5 years and 9 years, and conducted whole-body DXA scans at the 9-year clinical visit. Our study included 366 mother-child pairs with DXA scans and at least one PFAS measurement. We estimated covariate-adjusted associations of individual PFAS concentrations with age-, sex- and height-adjusted aBMD z-scores using multivariable regression models and applied formal mediation analysis to estimate the possible impact of by several measures of body composition. We also evaluated whether associations were modified by child sex. Results: We found PFAS exposures in childhood to be negatively associated with aBMD z-scores, with the strongest association seen for perfluorononanoic acid (PFNA) at age 5 years. A doubling in age-5 PFNA was associated with a 0.15 decrease in aBMD z-score (95% CI: − 0.26, − 0.039). The PFNA-aBMD association was significantly stronger in males than females, although effect modification by sex was not significant for other PFAS exposures. Results from the mediation analysis suggested that any potential associations between aBMD and 18-month PFAS concentrations may be mediated by total body fat and BMI, although most estimated total effects for PFAS exposures at age 18 months were non-significant. PFAS exposures at age 9 were not associated with age-9 aBMD z-scores. Conclusions: The PFAS-aBMD associations identified in this and previous studies suggest that bone may be a target tissue for PFAS. Pediatric bone density has been demonstrated to strongly track through young adulthood and possibly beyond; therefore, these prospective results may have important public health implications.

KW - Bone mass density

KW - Childhood

KW - DXA

KW - Per- and polyfluoroalkyl substances

KW - PFAS

U2 - 10.1186/s12940-022-00929-w

DO - 10.1186/s12940-022-00929-w

M3 - Journal article

C2 - 36402982

AN - SCOPUS:85142246407

VL - 21

JO - Environmental Health

JF - Environmental Health

SN - 1476-069X

M1 - 113

ER -

ID: 346048437